Skip to main content
Caplight Logo









MSICS Pharma

MSICS Pharma

Private
Ness ZionaHealthcare & Life Scienceshttps://msicspharma.com

Last Round

Seed

May 6, 2026

Total Funding Raised

$3.6M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

MSICS Pharma operates in Healthcare & Life Sciences and is based in Ness Ziona. Its latest recorded funding round was a Seed round in May 2026.

MSICS Pharma is a biotechnology company developing medical-grade technology to grow and produce psilocybin for the treatment of mental health conditions such as PTSD, depression, and OCD.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Non-AI

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

MSICS Pharma Comparables

Compare MSICS Pharma with similar companies based on industry and business-model similarity.

MSICS Pharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Xentria, Inc.
78%
Roivant Sciences
77%
SarcoMed USA
76%
Book a demo to see all comparables

For institutional investors. Book with your work email.

MSICS Pharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedMay 6, 2026
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

MSICS Pharma Investors

Notable investors and investment history

MSICS Pharma investors
InvestorRounds
FUSIONSeed
GlenRock IsraelSeed
SGL AcquisitionsSeed
L& VenturesSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 6, 2026

    $3.6M round led by FUSION.

Book a demo to see all signals

For institutional investors. Book with your work email.

MSICS Pharma Filings

Explore SEC and related filing metadata, where available.

MSICS Pharma filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about MSICS Pharma's valuation, stock price, and market status.

Is MSICS Pharma a public or private company?

MSICS Pharma is a private company.

What is the current stock price of MSICS Pharma?

MSICS Pharma is a private company, so its shares have no public market price. Caplight tracks MSICS Pharma's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is MSICS Pharma worth (valuation)?

Valuation information for MSICS Pharma is not publicly available.

Can I buy MSICS Pharma stock?

MSICS Pharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was MSICS Pharma's last funding round?

MSICS Pharma's most recent funding round was Seed on May 6, 2026.

Who are the main investors in MSICS Pharma?

Key investors in MSICS Pharma include FUSION, GlenRock Israel, SGL Acquisitions.

Will MSICS Pharma IPO soon?

No public IPO plans have been announced for MSICS Pharma.

How can I track MSICS Pharma secondary market activity?

Caplight tracks bids, offers, and trades in MSICS Pharma's shares on secondary markets.

Firmographic Details

HeadquartersNess Ziona
Year Founded2020
Last FundingMay 6, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?